Market Overview

UPDATE: Compass Point Upgrades DR Horton to Neutral on Updated Forecasts

Share:
Related DHI
Why 1 Analyst Just Raised Price Targets On These 7 Homebuilders
Citi Dishes On Housing, Details 'The Good, The (Less) Bad And The (Not So) Ugly'
Homebuilders Cheerful for Spring Selling Season - Analyst Blog (Zacks)

Compass Point raised its rating on DR Horton (NYSE: DHI) from Sell to Neutral and raised its price target to $18.50.

Compass Point commented, "After a full model update we are raising estimates and, coupled with the stock's relative underperformance in the post-QE3 trade, we now feel DHI should perform in line with the rest of the space. Our price target increase reflects our increased 2013 EPS estimate to $0.93 from $0.87 as well as a consistent 5% assumed ROI. We still see downside in the shares to $18 but the stock is off 12% since the Fed announced QE3 in early September and has been the second worst performer in the homebuilding sector over that time frame."

DR Horton closed at $19.58 on Wednesday.

Latest Ratings for DHI

DateFirmActionFromTo
Jan 2015CitigroupDowngradesBuyNeutral
Jan 2015UBSDowngradesBuyNeutral
Jan 2015Morgan StanleyInitiates Coverage onEqualweight

View More Analyst Ratings for DHI
View the Latest Analyst Ratings

Posted-In: Compass PointAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (DHI)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→